Alto Neuroscience, Inc.

NYSE:ANRO Stock Report

Market Cap: US$66.1m

Alto Neuroscience Management

Management criteria checks 1/4

Alto Neuroscience's CEO is Amit Etkin, appointed in Mar 2019, has a tenure of 6.17 years. total yearly compensation is $4.07M, comprised of 14.8% salary and 85.2% bonuses, including company stock and options. directly owns 4.45% of the company’s shares, worth $2.94M. The average tenure of the management team and the board of directors is 2.4 years and 2.3 years respectively.

Key information

Amit Etkin

Chief executive officer

US$4.1m

Total compensation

CEO salary percentage14.8%
CEO tenure6.2yrs
CEO ownership4.5%
Management average tenure2.4yrs
Board average tenure2.3yrs

Recent management updates

Recent updates

Alto Neuroscience (NYSE:ANRO) Has Debt But No Earnings; Should You Worry?

Nov 22
Alto Neuroscience (NYSE:ANRO) Has Debt But No Earnings; Should You Worry?

Alto Neuroscience: Potential First-In-Class Approach To Targeting CNS Disorders

Mar 21

CEO Compensation Analysis

How has Amit Etkin's remuneration changed compared to Alto Neuroscience's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024US$4mUS$603k

-US$61m

Sep 30 2024n/an/a

-US$57m

Jun 30 2024n/an/a

-US$50m

Mar 31 2024n/an/a

-US$42m

Dec 31 2023US$2mUS$393k

-US$36m

Compensation vs Market: Amit's total compensation ($USD4.07M) is above average for companies of similar size in the US market ($USD670.70K).

Compensation vs Earnings: Amit's compensation has increased whilst the company is unprofitable.


CEO

Amit Etkin (47 yo)

6.2yrs

Tenure

US$4,065,848

Compensation

Dr. Amit Etkin, MD, PhD., is the Founder of Alto Neuroscience, Inc. and has been its Chairman of the Board and Chief Executive Officer since March 2019, President since November 2023 and serves as its Dire...


Leadership Team

NamePositionTenureCompensationOwnership
Amit Etkin
Founder6.2yrsUS$4.07m4.45%
$ 2.9m
Nicholas Smith
CFO & Chief Business Officer2.5yrsUS$2.00m0.028%
$ 18.8k
Michael Hanley
Chief Operating Officer1yrUS$2.50m0%
$ 0
Dan Segal
Co-Founder & Strategic Advisorno datano data3.32%
$ 2.2m
Erin McQuade
General Counsel2.3yrsno datano data
Adam Savitz
Chief Medical Officer3.8yrsUS$1.35m0.15%
$ 97.2k
Jessica Powell
Chief Development Officer1.7yrsno datano data

2.4yrs

Average Tenure

49yo

Average Age

Experienced Management: ANRO's management team is considered experienced (2.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Amit Etkin
Founder6.2yrsUS$4.07m4.45%
$ 2.9m
Dan Segal
Co-Founder & Strategic Advisorless than a yearno data3.32%
$ 2.2m
Gwill York
Independent Director3.7yrsUS$426.24k0.088%
$ 58.4k
Alan Schatzberg
Scientific Advisorno datano datano data
Andrew Dreyfus
Independent Director1.6yrsUS$418.83k0%
$ 0
Madhukar Trivedi
Advisorno datano datano data
Husseini Manji
Non-Employee Independent Director1.3yrsUS$410.14k0%
$ 0
Po Chen
Non-Employee Independent Director3.1yrsUS$414.93k0.18%
$ 116.4k
Thomas Insel
Scientific Advisorno datano datano data
Mahalakshmi Radhakrishnan
Independent Director1.2yrsUS$383.89k0%
$ 0
Christopher Cox
Lead Independent Director3.1yrsUS$441.99k0%
$ 0
Quentin Huys
Scientific Advisorno datano datano data

2.3yrs

Average Tenure

63.5yo

Average Age

Experienced Board: ANRO's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/05 10:19
End of Day Share Price 2025/05/05 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alto Neuroscience, Inc. is covered by 8 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Patrick TrucchioH.C. Wainwright & Co.
Lin TsaiJefferies LLC